Search Results
Is teprotumumab better than steroids in TED associated compressive optic neuropathy?
Teprotumumab was found to be a rapid and effective treatment in 2 patients with thyroid eye disease associated compressive optic...
Read MorePrevent Blindness Talks Sight-Saving Drug Shortage During COVID-19 Efforts
Mark Dlugoss: Hello, this is Mark Dlugoss, Senior Contributing Editor for Ophthalmology 360. Welcome to the Ophthalmic Project powered by Ophthalmology...
Read MoreTED biomarkers provide potential information for therapeutic targets
A regulatory pathway of biomarkers for thyroid eye disease (TED) was constructed by researchers to help diagnose TED and understand...
Read MoreMajority of proptosis responders maintain long-term response with teprotumumab
Results from a study to assess long-term proptosis response and diplopia grade in patients treated with teprotumumab (Tepezza, Horizon) for...
Read MoreUse of automated imaging metrics in TED may provide rapid clinical information
The use of automated imaging metrics in thyroid eye disease has the potential to provide rapid clinical information that could...
Read MoreTeprotumumab reduces proptosis in patients with non-inflammatory TED
Teprotumumab, a human monoclonal anti-IGF-1R blocking antibody, reduced proptosis in a series of patients with non-inflammatory thyroid eye disease (TED),...
Read MoreTeprotumumab leads to ‘Unprecedented’ proptosis reduction in patients with TED
Use of the insulin-like growth factor I receptor teprotumumab led to long-term improvements in individuals with thyroid eye disease (TED), said Raymond...
Read MoreTED found in younger ages in Asians, Hispanics
Thyroid eye disease (TED) is found in younger ages in Asians and Hispanics compared with African Americans and Caucasians, according...
Read MoreLong-term data demonstrates sustained response with teprotumumab for TED
Long-term clinical trial follow-up data showed a sustained response up to 1 year following treatment for thyroid eye disease (TED)...
Read MoreData From Phase 3 Clinical Trial of Teprotumumab Demonstrates Improvements in Proptosis, Quality of Life
Patients with active thyroid eye disease who were treated with teprotumumab had significant improvements in proptosis, diplopia, and quality of...
Read MoreTeprotumumab reduces double vision, improves quality of life in TED
Results from the phase 3 OPTIC study showed teprotumumab (Horizon Therapeutics) significantly reduced double vision and improved quality of life...
Read More
Contact Info
